| Date |
Title |
| Nov 19, 2024 |
Illumina announces expansion of TruSight Oncology portfolio |
| Nov 12, 2024 |
Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says |
| Nov 6, 2024 |
Illumina To Webcast Upcoming Investor Conferences |
| Nov 4, 2024 |
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024 |
| Oct 31, 2024 |
Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting |
| Oct 9, 2024 |
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers |
| Oct 7, 2024 |
Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024 |
| Oct 3, 2024 |
Charles Dadswell to step down as General Counsel, Illumina initiates search for successor |
| Sep 3, 2024 |
European Court of Justice rules in favor of Illumina in jurisdictional appeal |
| Aug 27, 2024 |
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies |
| Aug 13, 2024 |
Illumina announces strategy to accelerate value creation |
| Aug 6, 2024 |
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024 |
| Aug 5, 2024 |
Illumina launches new oncology menu for NovaSeq X Series customers |
| Jul 18, 2024 |
Illumina to Present Upcoming Strategy Update |
| Jul 11, 2024 |
Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 |
| Jul 9, 2024 |
Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base |
| Jun 24, 2024 |
Illumina completes the divestiture of GRAIL |
| Jun 11, 2024 |
Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations |
| Jun 4, 2024 |
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost |
| Jun 3, 2024 |
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares |
| Jun 3, 2024 |
Illumina appoints Everett Cunningham Chief Commercial Officer |
| May 29, 2024 |
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO |
| May 28, 2024 |
Illumina releases 2023 Corporate Social Responsibility Report |
| May 20, 2024 |
Anna Richo joins Illumina's Board of Directors |
| May 15, 2024 |
Illumina To Webcast Upcoming Investor Conference |
| May 6, 2024 |
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL |
| May 3, 2024 |
Illumina To Webcast Upcoming Investor Conference |
| May 2, 2024 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024 |
| Apr 12, 2024 |
Illumina's planned divestment of GRAIL approved by the European Commission |
| Apr 9, 2024 |
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer |
| Apr 4, 2024 |
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024 |
| Feb 8, 2024 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023 |
| Jan 9, 2024 |
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023 |
| Jan 5, 2024 |
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test |
| Jan 4, 2024 |
Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024 |
| Jan 4, 2024 |
The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk |